NCT03070392已完成2 期
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 378
- 试验地点
- 57
- 主要终点
- Efficacy: Overall Survival
研究概览
简要总结
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
详细描述
This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A*0201 positive adult patients with advanced UM treated in the first line setting with no prior systemic or liver-directed chemo-, radio- or immune-therapy administered in the advanced setting (prior surgical resection of liver metastases and adjuvant systemic therapy are acceptable). Comparison of the IMCgp100 efficacy results in this Phase II study will be made with the concurrently randomized arm (Investigator's Choice) with a primary endpoint of overall survival (OS) and secondary efficacy endpoints of progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and disease control rate (DCR).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female participants age ≥ 18 years of age at the time of informed consent
- •Ability to provide and understand written informed consent prior to any study procedures
- •Histologically or cytologically confirmed metastatic UM
- •Must meet the following criteria related to prior treatment:
- •No prior systemic therapy in the metastatic or advanced setting including chemotherapy, immunotherapy, or targeted therapy
- •No prior regional, liver-directed therapy including chemotherapy, radiotherapy, or embolization
- •Prior surgical resection of oligometastatic disease is allowed
- •Prior neoadjuvant or adjuvant therapy is allowed provided administered in the curative setting in participants with localized disease. Participants may not be re-treated with an Investigator's Choice therapy that was administered as adjuvant or neoadjuvant treatment. Additionally, participants who have received nivolumab as prior adjuvant/neoadjuvant treatment should not receive pembrolizumab as Investigator's Choice therapy.
- •HLA A*0201 positive by central assay
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at Screening
- •Participants have measurable disease or non-measurable disease according to RECIST v1.1
- •All other relevant medical conditions must be well-managed and stable, in the opinion of the investigator, for at least 28 days prior to first administration of study drug
排除标准
- •Out-of-range laboratory values
- •History of severe hypersensitivity reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies
- •Clinically significant cardiac disease or impaired cardiac function,
- •Presence of symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require doses of corticosteroids within the prior 3 weeks to study Day
- •Participants with brain metastases are eligible if lesions have been treated with localized therapy and there is no evidence of PD for at least 4 weeks by magnetic resonance imaging (MRI) prior to the first dose of study drug
- •Active infection requiring systemic antibiotic therapy. Participants requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to the first dose of study drug
- •Known history of human immunodeficiency virus infection (HIV). Testing for HIV status is not necessary unless clinically indicated
- •Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection
- •Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type
- •Any medical condition that would, in the investigator's or Sponsor's judgment, prevent the participants participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results
- •Participants receiving systemic steroid therapy or any other systemic immunosuppressive medication at any dose level, as these may interfere with the mechanism of action of study treatment. Local steroid therapies (eg, otic, ophthalmic, intra-articular, or inhaled medications) are acceptable
- •History of adrenal insufficiency
- •History of interstitial lung disease
- •History of pneumonitis that required corticosteroid treatment or current pneumonitis
- •History of colitis or inflammatory bowel disease
- •Major surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary)
- •Radiotherapy within 2 weeks of the first dose of study drug, with the exception of palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass
- •Use of hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF, M-CSF) ≤ 2 weeks prior to start of study drug. An erythroid-stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment and the patient is not red blood cell transfusion dependent
- •Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation)
- •Women of childbearing potential who are sexually active with a non-sterilized male partner, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective contraception during study treatment (defined in Section 6.7), and must agree to continue using such precautions for 6 months after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician. Highly effective methods of contraception are described in Section 6.7
- •Male participants must be surgically sterile or use double barrier contraception methods from enrollment through treatment and for 6 months following administration of the last dose of study drug
- •Participant who are in an institution due to official or judicial order.
- •Participant who are the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in the conduct of the study.
- •Contraindication for treatment with Investigator's Choice alternatives (dacarbazine, ipilimumab and pembrolizumab) as per applicable labelling. Participant may have a contraindication to 1 or 2 of the choices if he/she is a candidate for dosing with at least 1 Investigator's Choice and meets all other study eligibility criteria.
研究组 & 干预措施
Investigator's Choice
Active Comparator
1 of 3 Investigator's Choice options: Systemic Dacarbazine
1 of 3 Investigator's Choice options: Systemic Ipilimumab
1 of 3 Investigator's Choice options: Systemic Pembrolizumab
干预措施: Pembrolizumab (Biological)
Investigator's Choice
Active Comparator
1 of 3 Investigator's Choice options: Systemic Dacarbazine
1 of 3 Investigator's Choice options: Systemic Ipilimumab
1 of 3 Investigator's Choice options: Systemic Pembrolizumab
干预措施: Ipilimumab (Biological)
IMCgp100 (tebentafusp, Kimmtrak)
Experimental
Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
干预措施: IMCgp100 (Biological)
Investigator's Choice
Active Comparator
1 of 3 Investigator's Choice options: Systemic Dacarbazine
1 of 3 Investigator's Choice options: Systemic Ipilimumab
1 of 3 Investigator's Choice options: Systemic Pembrolizumab
干预措施: Dacarbazine (Drug)
结局指标
主要结局
Efficacy: Overall Survival
时间窗: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.
Overall survival is defined as the time from randomization to date of death due to any cause.
次要结局
- Efficacy: Duration of Response (DOR)(DOR will be assessed every 3 months from randomization until disease progression, assessed up to 5.5 years.)
- Efficacy: Progression Free Survival (PFS)(PFS was assessed every 3 months from randomization until disease progression or death, up to 36 months.)
- Efficacy: Objective Response Rate (ORR)(ORR will be assessed after every participant has had at least 3 assessments, conducted every 3 months, up to 5.5 years.)
- Efficacy: Disease Control Rate (DCR)(DCR will be assessed every 3 months from randomization until disease progression, up to 5.5 years.)
- Quality-of-life: Change From Baseline in EQ-5D Visual Analogue Score (VAS)(EQ-5D,5L VAS was assessed at baseline (Cycle 1 Day 1) and on Day 1 of every other cycle to Cycle 5 Day 1, every fourth cycle thereafter, beginning with Cycle 9 Day 1 and End of Treatment (EOT), up to 36 months. Each cycle is 21 days.)
- Pharmacokinetics (PK): Tebentafusp Concentration(PK concentrations were assessed at pre-dose, end of infusion and anytime in the 12 to 24 hour window after completion of the infusion in Cycle 1 on Days 1, 8 and 15.)
- Quality-of-Life: Change From Baseline in EQ-5D,5L Domain Scores(EQ-5D,5L was assessed at baseline (Cycle 1 Day 1) and on Day 1 of every other cycle to Cycle 5 Day 1, every fourth cycle thereafter, beginning with Cycle 9 Day 1 and End of Treatment (EOT), up to 36 months. Each cycle is 21 days.)
- Safety: Number of Participants With Treatment Emergent Adverse Events(Safety was assessed from informed consent through 90 days after end of treatment, up to 36 months.)
- Quality-of-Life: Change From Baseline in EORTC QLQ-C30 Global Health Status(EORTC QLQ-C30 was assessed at baseline (Cycle 1 Day 1) and on Day 1 of every other cycle to Cycle 5 Day 1, every fourth cycle thereafter, beginning with Cycle 9 Day 1 and End of Treatment (EOT), up to 36 months. Each cycle is 21 days.)
- Pharmacokinetics: Frequency of Anti-IMCgp100 Antibody Formation(Approximately 5 assessments will be performed between first dose of IMCgp100 and end of treatment, assessed up to 5.5 years.)
研究者
研究点 (57)
Loading locations...
相似试验
已完成
2 期
A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch MutationsAdenoid Cystic CarcinomaNCT03691207Ayala Pharmaceuticals, Inc,87
尚未招募
2 期
A Clinical Study of 6MW3211 in Patients With Renal CancerAdvanced Clear Cell Renal Cell CarcinomaNCT05440045Mabwell (Shanghai) Bioscience Co., Ltd.30
终止
2 期
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial CarcinomaUrothelial CarcinomaNCT01353222Dendreon142
已完成
2 期
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric CancerAdenocarcinoma - GEJCancer of EsophagusNCT04984733University of Southampton13
已完成
1 期
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerEsophagogastric Junction AdenocarcinomaGastric CancerEsophageal CancerNCT00719550Amgen130